The increased frequency of latent benign nodules and the reduced incidence of de-novo malignant mammary tumors in the BCCIP-CKD group suggest that BCCIP downregulation may promote the initiation of mammary tumor formation but prohibit the de-novo tumor progression. The gene discussed is BCCIP; the disease is breast cancer.